Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

(2023) Chong Qiu et al.   International Journal of Biological Sciences

Natural bioactive compounds-doxorubicin combinations targeting topoisomerase II-alpha: Anticancer efficacy and safety

(2023) Ahmed Elfadadny et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

PD-1/PD-L1 and DNA Damage Response in Cancer

(2023) Mateusz Kciuk et al.   Cells

Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches

(2022) Mohammad Sheibani et al.   Cardiovascular Toxicology

A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives

(2022) Peng Liu et al.   MOLECULES

Amplification of ferroptosis with a liposomal nanoreactor cooperates with low-toxicity doxorubicin apoptosis for enhanced tumor chemotherapy

(2022) Peng Ji et al.   Biomaterials Science

Encapsulation, Release, and Cytotoxicity of Doxorubicin Loaded in Liposomes, Micelles, and Metal-Organic Frameworks: A Review

(2022) Mihad Ibrahim et al.   Pharmaceutics

Cyclin-dependent kinases in DNA damage response

(2022) Mateusz Kciuk et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Simultaneous proteasome and autophagy inhibition synergistically enhances cytotoxicity of doxorubicin in breast cancer cells

(2022) Jian Sheng Loh et al.   CELL BIOCHEMISTRY AND FUNCTION

Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response

(2022) Mateusz Kciuk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ferroptosis: A New Road towards Cancer Management

(2022) Iqra Bano et al.   MOLECULES

DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion

(2022) Baiwen Chen et al.   Nature Communications

Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic

(2022) Ana Isabel Fraguas-Sánchez et al.   Cancers

Cancer-associated transcription factors in DNA damage response

(2022) Mateusz Kciuk et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Liposomal doxorubicin supercharge‐containing front‐line treatment in patients with advanced‐stage diffuse large B‐cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single‐centre phase II study

(2022) Marco Picardi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

(2022) Patricia Pautier et al.   LANCET ONCOLOGY

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer

(2022) Tiantian Wang et al.   JAMA Oncology

Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies

(2022) Wuyin Wang et al.   Cancer Biology & Medicine

Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft tissue sarcoma: a prospective, single-arm phase II study

(2022) Xin Liu et al.   CLINICAL CANCER RESEARCH

A systematic review of published clinical trials in the systemic treatment of adrenocortical carcinoma: An initiative led on behalf of the Global Society of Rare Genitourinary Tumors

(2022) Tiago Costa de Padua et al.   Clinical Genitourinary Cancer

Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer

(2022) Prakash S. S． et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma

(2022) Jiefei Zhu et al.   IMMUNOGENETICS

Doxorubicin-induced senescence in normal fibroblasts promotes in vitro tumour cell growth and invasiveness: The role of Quercetin in modulating these processes

(2022) Elisa Bientinesi et al.   MECHANISMS OF AGEING AND DEVELOPMENT

Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs

(2022) Rodrigo dos A. Miguel et al.   Pharmaceutics

The Synergistic Effects of Curcumin and Chemotherapeutic Drugs in Inhibiting Metastatic, Invasive and Proliferative Pathways

(2022) Maria Younes et al.   Plants-Basel

Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity

(2022) Iman Moustafa et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

MRN complex is an essential effector of DNA damage repair

(2021) Shan Qiu et al.   Journal of Zhejiang University-SCIENCE B

Doxorubicin‐induced senescence promotes stemness and tumorigenicity in EpCAM−/CD133− nonstem cell population in hepatocellular carcinoma cell line, HuH‐7

(2021) Mustafa Karabicici et al.   Molecular Oncology

Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma

(2021) Stefan Antonowicz et al.   Nature Communications

Induction of Pyroptosis: A Promising Strategy for Cancer Treatment

(2021) Lei Wang et al.   Frontiers in Oncology

Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity

(2021) Suah Yang et al.   BIOMATERIALS

ROS-induced cell cycle arrest as a mechanism of resistance in polyaneuploid cancer cells (PACCs)

(2021) Morgan D. Kuczler et al.   PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY

Regulated cell death pathways in doxorubicin-induced cardiotoxicity

(2021) Effimia Christidi et al.   Cell Death & Disease

Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

(2021) María Merino et al.   JOURNAL OF NANOBIOTECHNOLOGY

Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management

(2021) Pushkar Singh Rawat et al.   BIOMEDICINE & PHARMACOTHERAPY

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells

(2021) Andrea Ghelli Luserna Di Rorà et al.   CELL BIOLOGY AND TOXICOLOGY

Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer

(2021) Jafar Amani et al.   DNA REPAIR

PARP1: Structural insights and pharmacological targets for inhibition

(2021) Jacob O. Spiegel et al.   DNA REPAIR

Caspase‐3‐mediated GSDME induced Pyroptosis in breast cancer cells through the ROS/JNK signalling pathway

(2021) Ziwen Zhang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Neuroprotective Potential of Berberine Against Doxorubicin-Induced Toxicity in Rat’s Brain

(2021) Ghadha Ibrahim Fouad et al.   NEUROCHEMICAL RESEARCH

Mechanisms of doxorubicin-mediated reproductive toxicity – A review

(2021) Uma Priya Mohan et al.   REPRODUCTIVE TOXICOLOGY

Iron-doxorubicin prodrug loaded liposome nanogenerator programs multimodal ferroptosis for efficient cancer therapy

(2021) Yinxian Yang et al.   Asian Journal of Pharmaceutical Sciences

DNA-PKcs: a targetable pro-tumorigenic protein kinase

(2021) Emanuela Dylgjeri et al.   CANCER RESEARCH

Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy

(2021) Muhammad Sohail et al.   Expert Review of Anticancer Therapy

Co-delivery of the autophagy inhibitor si-Beclin1 and the doxorubicin nano-delivery system for advanced prostate cancer treatment

(2021) Chuling Hu et al.   JOURNAL OF BIOMATERIALS APPLICATIONS

Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity

(2020) Maria A. Mitry et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage

(2020) Chao Mei et al.   BIOMEDICINE & PHARMACOTHERAPY

DNA-protein crosslink formation by endogenous aldehydes and AP sites

(2020) Jun Nakamura et al.   DNA REPAIR

Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors

(2020) Sabrina Dallavalle et al.   DRUG RESISTANCE UPDATES

Mechanisms of Multidrug Resistance in Cancer Chemotherapy

(2020) Karol Bukowski et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD‑L1 expression increased by IFN‑γ via JAK2‑STAT1 signaling and predicts a poor survival in colorectal cancer

(2020) Tiancheng Zhao et al.   Oncology Letters

Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO3 nanoformulation triggers ferroptosis in target tumor cells

(2020) Chen-Cheng Xue et al.   Science Advances

Nitrogen Containing Heterocycles as Anticancer Agents: An Overview

(2020) Damanpreet K. Lang et al.   Anti-Cancer Agents in Medicinal Chemistry

The Determining Role of Mitochondrial Reactive Oxygen Species Generation and Monoamine Oxidase Activity in Doxorubicin-Induced Cardiotoxicity

(2020) Salvatore Antonucci et al.   ANTIOXIDANTS & REDOX SIGNALING

Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview

(2020) Mateusz Kciuk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

New molecular and biochemical insights of doxorubicin-induced hepatotoxicity

(2020) Pureti Lakshmi Prasanna et al.   LIFE SCIENCES

Doxorubicin generates senescent microglia that exhibit altered proteomes, higher levels of cytokine secretion, and a decreased ability to internalize amyloid β

(2020) Luís Marques et al.   EXPERIMENTAL CELL RESEARCH

New insights into the activities and toxicities of the old anticancer drug doxorubicin

(2020) Sabina Y. van der Zanden et al.   FEBS Journal

Focus on UV-Induced DNA Damage and Repair—Disease Relevance and Protective Strategies

(2020) Mateusz Kciuk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies

(2020) Aloke Sarkar et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The Synthesis of Nano-Doxorubicin and its Anticancer Effect.

(2020) Lusha Zhu et al.   Anti-Cancer Agents in Medicinal Chemistry

Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization

(2020) Vivek Makwana et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma

(2020) Maurizio Viale et al.   PHARMACOLOGICAL RESEARCH

DNA-PKcs: A Multi-Faceted Player in DNA Damage Response

(2020) Xiaoqiao Yue et al.   Frontiers in Genetics

Stem Cell-Derived Exosomes Ameliorate Doxorubicin-Induced Muscle Toxicity through Counteracting Pyroptosis

(2020) Fatima Bianca A. Dessouki et al.   Pharmaceuticals

Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates

(2020) Mahwash Mukhtar et al.   Chemosensors

PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution

(2019) Zahid Hussain et al.   Drug Delivery and Translational Research

Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy

(2019) Fakhrossadat Emami et al.   MOLECULAR PHARMACEUTICS

ROS-Induced Activation of DNA Damage Responses Drives Senescence-Like State in Postmitotic Cochlear Cells: Implication for Hearing Preservation

(2019) Nesrine Benkafadar et al.   MOLECULAR NEUROBIOLOGY

Doxorubicin-Induced Cardiotoxicity And Cardioprotective Agents: Classic And New Players In The Game.

(2019) Felipe dos Santos Arruda et al.   CURRENT PHARMACEUTICAL DESIGN

Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro

(2019) Pian Yu et al.   ACTA PHARMACOLOGICA SINICA

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Doxorubicin-induced neurotoxicity is associated with acute alterations in synaptic plasticity, apoptosis, and lipid peroxidation

(2019) Ahmad H. Alhowail et al.   TOXICOLOGY MECHANISMS AND METHODS

Doxorubicin-Induced Cancer Cell Senescence Shows a Time Delay Effect and Is Inhibited by Epithelial-Mesenchymal Transition (EMT)

(2019) Xuerui Hu et al.   MEDICAL SCIENCE MONITOR

Cisplatin contributes to programmed death-ligand 1 (PD-L1) expression in bladder cancer through ERK1/2 - AP-1 signaling pathway

(2019) Te-Fu Tsai et al.   BIOSCIENCE REPORTS

HMGB1 modulates the balance between senescence and apoptosis in response to genotoxic stress

(2019) Je-Jung Lee et al.   FASEB JOURNAL

Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma

(2019) Jizhuang Wang et al.   JOURNAL OF IMMUNOTHERAPY

Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring

(2019) Nadine Wenningmann et al.   MOLECULAR PHARMACOLOGY

Oxidative stress injury in doxorubicin-induced cardiotoxicity

(2019) Mei Songbo et al.   TOXICOLOGY LETTERS

Hallmarks of senescence and aging

(2019) Slavica Dodig et al.   Biochemia Medica

Doxorubicin‐induced senescence through NF‐κB affected by the age of mouse mesenchymal stem cells

(2019) Ali Bashiri Dezfouli et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The role of pyroptosis in cancer: pro-cancer or pro-“host”?

(2019) Xiaojing Xia et al.   Cell Death & Disease

Doxorubicin-Induced Oxidative Stress Differentially Regulates Proteolytic Signaling in Cardiac and Skeletal Muscle

(2019) Ryan Nestor Montalvo et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Arylboronate prodrugs of doxorubicin as promising chemotherapy for pancreatic cancer

(2019) Charles Skarbek et al.   BIOORGANIC CHEMISTRY

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

(2019) Ludovic Fournel et al.   CANCER LETTERS

Association of PD‐L1 expression status with the efficacy of PD‐1/PD‐L1 inhibitors and overall survival in solid tumours: A systematic review and meta‐analysis

(2019) Xi Liu et al.   INTERNATIONAL JOURNAL OF CANCER

Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3

(2019) Liping Meng et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination

(2019) Yosi Gilad et al.   Scientific Reports

Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo

(2019) Helena Besse et al.   Cancers

Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents

(2019) Agnieszka Bojko et al.   Cells

An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients

(2019) Alfonso Varela-López et al.   FOOD AND CHEMICAL TOXICOLOGY

Mechanisms of Anthracycline-Enhanced Reactive Oxygen Metabolism in Tumor Cells

(2019) James H. Doroshow   Oxidative Medicine and Cellular Longevity

Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?

(2019) Balaraman Kalyanaraman   Redox Biology

Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

(2018) Markella Konstantinidou et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The relationship between DNA single-stranded damage response and double-stranded damage response

(2018) Aiqing Ma et al.   CELL CYCLE

Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity

(2018) Eric M. Mastria et al.   JOURNAL OF CONTROLLED RELEASE

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

(2018) Hye Jeong Park et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Toxicity of Doxorubicin (Dox) to different experimental organ systems

(2018) Arivalagan Pugazhendhi et al.   LIFE SCIENCES

Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib

(2018) Stefania Gorini et al.   Oxidative Medicine and Cellular Longevity

Hallmarks of Cellular Senescence

(2018) Alejandra Hernandez-Segura et al.   TRENDS IN CELL BIOLOGY

Insight into the role of PIKK family members and NF-кB in DNAdamage-induced senescence and senescence-associated secretory phenotype of colon cancer cells

(2018) Anna Strzeszewska et al.   Cell Death & Disease

Chemoprotective effects of curcumin on doxorubicin-induced nephrotoxicity in wistar rats: by modulating inflammatory cytokines, apoptosis, oxidative stress and oxidative DNA damage

(2018) Fulya Benzer et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment

(2018) Seung Woo Chung et al.   BIOMATERIALS

Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer

(2018) John Wahba et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

(2018) Toshiki Iwai et al.   Oncotarget

Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells

(2018) Yuli Chang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Oxidative DNA damage & repair: An introduction

(2017) Jean Cadet et al.   FREE RADICAL BIOLOGY AND MEDICINE

Coordination of DNA single strand break repair

(2017) Rachel Abbotts et al.   FREE RADICAL BIOLOGY AND MEDICINE

Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations

(2017) Ruijuan Luo et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

PD-L1

(2017) Anthousa Kythreotou et al.   JOURNAL OF CLINICAL PATHOLOGY

To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes

(2017) Yannan Dou et al.   JOURNAL OF CONTROLLED RELEASE

Strategies to release doxorubicin from doxorubicin delivery vehicles

(2017) Juan Li et al.   JOURNAL OF DRUG TARGETING

Advances in nano-delivery systems for doxorubicin: an updated insight

(2017) Ummarah Kanwal et al.   JOURNAL OF DRUG TARGETING

Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model

(2017) Xinxin Zhu et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH

Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells

(2017) Mengqi Yang et al.   Molecular Oncology

The essential kinase ATR: ensuring faithful duplication of a challenging genome

(2017) Joshua C. Saldivar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines

(2017) Toshifumi Doi et al.   ONCOLOGY REPORTS

Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity

(2017) Donato Cappetta et al.   Oxidative Medicine and Cellular Longevity

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma

(2017) Chan-Young Ock et al.   Oncotarget

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

(2017) Shengwei Liu et al.   Oncotarget

Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

(2017) Linda Tran et al.   Cancer Immunology Research

Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes

(2017) Mari C. Asensio-López et al.   PLoS One

Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes

(2017) Liqun Zhao et al.   Scientific Reports

Activation of apoptosis signalling pathways by reactive oxygen species

(2016) Maureen Redza-Dutordoir et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells

(2016) Baoqing Guo et al.   BMC CANCER

Calreticulin, a therapeutic target?

(2016) Paul Eggleton et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model

(2016) Judith A. Smith et al.   GYNECOLOGIC ONCOLOGY

Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines

(2016) Nesstor Pilco-Ferreto et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery

(2016) Yuling Bao et al.   JOURNAL OF CONTROLLED RELEASE

Anticancer metal drugs and immunogenic cell death

(2016) Alessio Terenzi et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases

(2016) Pierpaola Davalli et al.   Oxidative Medicine and Cellular Longevity

Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma

(2016) MASANORI KAWANO et al.   Oncology Letters

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

(2016) Madison Black et al.   Oncotarget

PEGylation in anti-cancer therapy: An overview

(2016) Prajna Mishra et al.   Asian Journal of Pharmaceutical Sciences

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Mitochondria-Derived Reactive Oxygen Species Play an Important Role in Doxorubicin-Induced Platelet Apoptosis

(2015) Zhicheng Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma

(2015) Zuzanna Baranski et al.   JOURNAL OF PATHOLOGY

Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma

(2015) Meng-Tzu Weng et al.   Scientific Reports

Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment

(2015) Judith A Smith et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Enhanced Doxorubicin Delivery to the Brain Administered Through Glutathione PEGylated Liposomal Doxorubicin (2B3-101) as Compared with Generic Caelyx,®/Doxil®—A Cerebral Open Flow Microperfusion Pilot Study

(2014) Thomas Birngruber et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Autophagy prevents doxorubicin-induced apoptosis in osteosarcoma

(2014) DONGXU ZHAO et al.   Molecular Medicine Reports

Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release

(2014) Dmitry B. Zorov et al.   PHYSIOLOGICAL REVIEWS

Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)

(2014) Pieter J. Gaillard et al.   PLoS One

Cellular Levels of Oxidative Stress Affect the Response of Cervical Cancer Cells to Chemotherapeutic Agents

(2014) Maria Filippova et al.   Biomed Research International

Doxorubicin induces senescence and impairs function of human cardiac progenitor cells

(2013) Elena Piegari et al.   BASIC RESEARCH IN CARDIOLOGY

Targeting ATR in DNA damage response and cancer therapeutics

(2013) Emmanouil Fokas et al.   CANCER TREATMENT REVIEWS

Doxorubicin Enhances Nucleosome Turnover around Promoters

(2013) Fan Yang et al.   CURRENT BIOLOGY

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

(2013) Lára Hannesdóttir et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

(2013) M. A. Batey et al.   MOLECULAR CANCER THERAPEUTICS

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

Liposome: classification, preparation, and applications

(2013) Abolfazl Akbarzadeh et al.   Nanoscale Research Letters

Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy

(2012) Jose Prados et al.   Anti-Cancer Agents in Medicinal Chemistry

Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death

(2012) Thomas D. Mullen et al.   Anti-Cancer Agents in Medicinal Chemistry

During apoptosis HMGB1 is translocated into apoptotic cell-derived membraneous vesicles

(2012) Martin Schiller et al.   AUTOIMMUNITY

Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation

(2012) Robert A. Forrest et al.   BIOCHEMICAL PHARMACOLOGY

Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination

(2012) Sudjit Luanpitpong et al.   BIOCHEMICAL PHARMACOLOGY

Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity

(2012) Balindiwe J.N. Sishi et al.   BIOCHEMICAL PHARMACOLOGY

Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways

(2012) Jian Ma et al.   CARDIOVASCULAR RESEARCH

Immunoliposomes

(2012) E. Paszko et al.   CURRENT MEDICINAL CHEMISTRY

Doxorubicin-Induced In Vivo Nephrotoxicity Involves Oxidative Stress- Mediated Multiple Pro- and Anti-Apoptotic Signaling Pathways

(2012) Tejas S. Lahoti et al.   CURRENT NEUROVASCULAR RESEARCH

Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy

(2012) YAN-JUN ZHONG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

(2012) Oktay Tacar et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Induction of Cellular Senescence by Doxorubicin Is Associated with Upregulated miR-375 and Induction of Autophagy in K562 Cells

(2012) Ming-Yu Yang et al.   PLoS One

Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats

(2012) Summya Rashid et al.   TOXICOLOGY MECHANISMS AND METHODS

Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes

(2011) Laura A. A. Gilliam et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

(2011) S. R. Mattarollo et al.   CANCER RESEARCH

Mechanisms and management of doxorubicin cardiotoxicity

(2011) Y. Shi et al.   HERZ

Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells

(2011) David Davidson et al.   INVESTIGATIONAL NEW DRUGS

Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines

(2011) Maria Coimbra et al.   JOURNAL OF CONTROLLED RELEASE

Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

(2011) Twan Lammers et al.   JOURNAL OF CONTROLLED RELEASE

Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma

(2011) Matteo Dell'olio et al.   LEUKEMIA & LYMPHOMA

DNA damage induced by endogenous aldehydes: Current state of knowledge

(2011) Georgia-Persephoni Voulgaridou et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non-Hodgkin's Lymphoma Xenograft Mouse Model

(2010) J. M. Tuscano et al.   CLINICAL CANCER RESEARCH

The MRN complex in double-strand break repair and telomere maintenance

(2010) Brandon J. Lamarche et al.   FEBS LETTERS

Oxidatively generated base damage to cellular DNA

(2010) Jean Cadet et al.   FREE RADICAL BIOLOGY AND MEDICINE

Doxorubicin-Induced Thymus Senescence

(2010) Rukhsana Sultana et al.   JOURNAL OF PROTEOME RESEARCH

Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia Mangostana

(2010) J. Tangpong et al.   NEUROSCIENCE

Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs

(2010) D. Salerno et al.   NUCLEIC ACIDS RESEARCH

Doxorubicin pathways

(2010) Caroline F. Thorn et al.   Pharmacogenetics and Genomics

ATM Activation by Oxidative Stress

(2010) Z. Guo et al.   SCIENCE

Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells

(2010) Regine Lüpertz et al.   TOXICOLOGY

Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2

(2009) Paolo Spallarossa et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study

(2009) Jalid Sehouli et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Doxorubicin: The Good, the Bad and the Ugly Effect

(2009) Cristina Carvalho et al.   CURRENT MEDICINAL CHEMISTRY

How are nucleosomes disrupted during transcription elongation?

(2009) Jordanka Zlatanova et al.   HFSP Journal

Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB

(2009) Jae Yeo Park et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

(2009) Robert T. O’Donnell et al.   INVESTIGATIONAL NEW DRUGS

Divergence to apoptosis from ROS induced cell cycle arrest: Effect of cadmium

(2009) Soumya Chatterjee et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Doxorubicin Exerts Cytotoxic Effects through Cell Cycle Arrest and Fas-Mediated Cell Death

(2009) Hye-Sun Kim et al.   PHARMACOLOGY

Cellular responses to reactive oxygen species-induced DNA damage and aging

(2008) Catharina Bertram et al.   BIOLOGICAL CHEMISTRY

Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells

(2008) Malgorzata A. Sliwinska et al.   MECHANISMS OF AGEING AND DEVELOPMENT

ATR: an essential regulator of genome integrity

(2008) Karlene A. Cimprich et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations

(2008) K. E. Coldwell et al.   NUCLEIC ACIDS RESEARCH

Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab′ fragments and single chain Fv

(2007) Wilson W.K. Cheng et al.   JOURNAL OF CONTROLLED RELEASE